Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesTempus AI, Inc. Class A Common Stock

Tempus AI, Inc. Class A Common Stock

Healthcare Health Information Services
PortfolioPortfolio WatchlistWatchlist
Company price
75.66 USD -2.14 ( 2.75%)
Last update at 2026-11-04T18:30:00Z
VOLUME
4116517
Market Cap
12422.93M

Momentum Score

…

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
72.75
Low
81.60
High
52 Week Price Range
40.77
Low
104.32
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Tempus AI, Inc. operates a clinical-genomic data and analytics platform that applies machine learning to support precision medicine, providing sequencing, diagnostic services and software to healthcare and life‑science customers. Long-term growth may be driven by broader adoption of genomic testing, expansion of its curated clinical dataset, partnerships with providers and pharma, and recurring revenue from testing and analytics. Investors may find the company attractive because its large longitudinal data assets and AI capabilities appear positioned to support differentiated clinical decision tools and research collaborations.

Primary investment risks include reimbursement and regulatory uncertainty for diagnostics, intense competition from established and emerging genomics players, execution and scalability challenges in commercializing services, and reliance on continued data access and model performance.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
77.80
Dividend Yield
-
Revenue TTM
1432.02M
Revenue Per Share
8.05
Gross Profit TTM
916.19M
Debt / Equity
2.70
ROE
-67.44%
Net Debt
722.34M
ROCE
-11.61%
Diluted EPS TTM
-1.44

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -296.71M -705.54M -213.83M -289.15M -258.59M
Net income -245.03M -705.81M -214.12M -289.81M -259.19M
Selling general administrative 715.43M 755.35M 296.76M 233.38M 199.00M
Gross profit 797.90M 381.11M 286.18M 121.68M 77.39M
Reconciled depreciation 102.32M 37.24M 33.33M 30.41M 23.88M
Ebit -220.83M -647.66M -166.66M -267.26M -243.40M
Ebitda -118.51M -610.42M -133.33M -236.85M -219.52M
Depreciation and amortization 102.32M 37.24M 33.33M 30.41M 23.88M
Operating income -252.87M -691.08M -196.08M -269.14M -243.98M
Other operating expenses 1524.66M 1384.48M 727.90M 589.81M 501.83M
Interest expense 70.27M 53.65M 46.87M 21.89M 15.18M
Tax provision -51.68M 0.27M 0.29M 0.07M 0.00M
Interest income 12.63M 11.08M 7.60M 3.03M 0.62M
Net interest income -57.64M -42.57M -39.27M -18.86M -14.56M
Income tax expense -51.68M 0.27M 0.29M 0.07M 0.60M
Total revenue 1271.79M 693.40M 531.82M 320.67M 257.85M
Total operating expenses 1050.77M 1072.19M 482.26M 390.82M 321.37M
Cost of revenue 473.89M 312.29M 245.65M 198.99M 180.46M
Total other income expense net -43.84M -14.46M -17.75M -23.71M -14.61M
Net income from continuing ops -245.03M -705.81M -214.12M -289.81M -259.19M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2274.84M 926.12M 564.05M 631.36M 531.35M
Intangible assets 355.25M 11.72M 21.92M 37.28M 37.29M
Other current assets 40.50M 26.14M 24.61M 19.45M 17.29M
Total liab 1783.51M 869.78M 1946.21M 734.25M 440.55M
Total stockholder equity 491.33M 56.34M -1382.16M -102.88M 90.80M
Other current liab 168.41M 114.43M 171.77M 71.75M 64.18M
Common stock 0.02M 0.02M 0.01M 0.01M 0.01M
Capital stock 0.02M 0.02M 0.01M 0.01M 0.01M
Retained earnings -2395.86M -2150.83M -1396.92M -1138.30M -807.49M
Good will 470.21M 73.34M 73.35M 53.10M 15.98M
Cash 604.79M 340.95M 165.77M 302.94M 277.69M
Total current liabilities 372.39M 291.07M 232.63M 174.24M 114.81M
Current deferred revenue 108.63M 91.94M 64.86M 50.14M 16.45M
Net debt 722.34M 127.14M 322.38M 130.09M -38.74M
Short term debt 13.36M 6.46M 6.44M 6.36M 0.42M
Short long term debt total 1327.13M 468.09M 488.14M 433.03M 238.95M
Other stockholder equity 2886.27M 2207.06M -1090.80M 9.25M -
Total current assets 1167.17M 667.60M 350.33M 433.35M 400.13M
Long term investments 86.56M 91.45M - - -
Short term investments 150.21M 107.31M 31.81M 0.00M -
Net receivables 319.95M 154.82M 99.31M 88.68M 82.24M
Long term debt 1239.50M 435.44M 449.67M 389.55M 238.24M
Inventory 51.72M 38.39M 28.84M 22.28M 22.91M
Accounts payable 81.99M 53.80M 54.42M 45.99M 33.75M
Accumulated other comprehensive income 0.90M 0.09M 0.01M 0.02M -0.01M
Non currrent assets other 41.99M 9.19M 36.24M 14.11M 10.71M
Non current assets total 1107.66M 258.51M 213.72M 198.01M 131.22M
Capital lease obligations 87.63M 32.66M 38.48M 43.48M 0.71M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 5.58M -130.39M -40.31M -57.94M -21.72M
Total cashflows from investing activities -398.36M -130.39M - - -
Net borrowings 735.76M 0.00M - - -
Total cash from financing activities 884.12M 494.33M 117.55M 251.39M -2.04M
Net income -245.03M -705.81M -214.12M -289.81M -259.19M
Change in cash 267.62M 175.23M -137.12M 25.25M -235.75M
Begin period cash flow 341.83M 166.61M 303.73M 277.69M 513.44M
End period cash flow 609.45M 341.83M 166.61M 302.94M 277.69M
Total cash from operating activities -218.09M -189.04M -214.34M -168.20M -211.98M
Issuance of capital stock 195.50M 581.70M 44.88M 92.20M 8.89M
Depreciation 102.32M 37.24M 33.33M 30.41M 23.88M
Other cashflows from investing activities -6.22M -95.19M - - -4.00M
Dividends paid 0.00M 5.62M 5.62M 5.62M 5.62M
Change to inventory -3.37M -9.54M -6.56M -1.31M 14.65M
Change to account receivables -90.40M -61.04M -7.35M -8.20M 4.75M
Sale purchase of stock -3.04M -2.25M -3.60M 0.00M 0.00M
Other cashflows from financing activities -44.10M 118.00M 44.19M 86.77M 4.38M
Capital expenditures 27.27M 22.12M 34.61M 18.38M 11.77M
Change in working capital -178.55M -37.80M -37.84M 71.82M 14.55M
Stock based compensation 124.75M 534.14M - 0.00M 0.56M
Other non cash items 31.08M -16.82M 4.28M 97.63M 67.62M
Free cash flow -245.35M -211.17M -248.95M -186.58M -223.75M

Peer Comparison*

Sector: Healthcare Industry: Health Information Services

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
TEM
Tempus AI, Inc. Class A Common Stock		 -2.14
2.75%		 75.66 - - 8.68 25.39 8.33
VEEV
Veeva Systems Inc Class A		 5.51
1.82%		 308.72 43.49 29.59 12.48 5.79 10.39
PMCUF
Pro Medicus Limited		 -
-%		 132.14 64.90 90.91 49.11 38.05 65.12
MTHRY
M3 Inc		 -0.65
11.40%		 5.05 31.84 26.25 0.05 4.60 0.04
BTSG
BrightSpring Health Services, Inc. Common Stock		 -
-%		 69.84 100.22 40.65 0.69 4.92 0.92

Profile*

Tempus AI, Inc. Class A Common Stock

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

600 West Chicago Avenue, Chicago, IL, United States, 60654

800 976 5448

https://www.tempus.com

3800

Name Title Year Born
Mr. Shane Colley Chief Technology Officer NA
Mr. Ryan M. Bartolucci CPA Chief Accounting Officer 1982
Mr. Eric P. Lefkofsky Co-Founder, CEO, President & Chairman 1970
Mr. James Rogers Chief Financial Officer 1986
Mr. Ryan Fukushima Chief Operating Officer 1985
Dr. Kate A. Sasser Ph.D. Chief Scientific Officer 1977
Mr. Erik Phelps Executive VP, Assistant Secretary and Chief Administrative & Legal Officer 1971
Ms. Patty Spiller Senior Vice President of Marketing NA
Ms. Christina Antoniou Senior VP & Head of Corporate Development NA
Ms. Stacey Kraft Chief People Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.34
+14.45%
OMG
CAD 1.70
+13.76%
ARTG
CAD 39.54
+12.59%
DSV
CAD 10.83
+12.58%
TLRY
CAD 4.17
+12.10%
DRUG
CAD 25.95
-30.02%
HUT
CAD 69.16
-22.20%
UCU
CAD 2.04
-16.39%
PHX
CAD 10.70
-15.62%
VET
CAD 15.04
-13.31%

Equity Sectors*

  • Basic Materials

    +4.80%

  • Communication Services

    +2.78%

  • Consumer Cyclical

    +2.82%

  • Consumer Defensive

    +0.74%

  • Energy

    -4.92%

  • Financial Services

    +2.47%

  • Healthcare

    -0.30%

  • Industrials

    -0.38%

  • Real Estate

    +1.75%

  • Technology

    +0.82%

  • Utilities

    +1.29%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…